12. Expansion Into Global Markets
As regulatory scrutiny intensified in the United States, pharmaceutical companies began to expand opioid sales overseas. They introduced similar marketing strategies in international markets, often downplaying addiction risks and promoting opioids for chronic pain. According to the Los Angeles Times, these actions threatened to replicate the U.S. epidemic abroad, risking a new wave of addiction and public health crises in vulnerable countries.
